AVE Science & Technology Co

AVE Science & Technology Co Debt/EBITDA

Total Debt to EBITDA Ratio of AVE Science & Technology Co (688067.SS) as of Oct 18, 2026.

Debt/EBITDA

0.00

Last updated:

Total Debt to EBITDA Ratio of AVE Science & Technology Co is 2025 0.00 . Total Debt to EBITDA Ratio of AVE Science & Technology Co was 2024 -2.39 . It decreases by % higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co Ltd, based in Changsha, China, operates in the Health Care sector, specializing in clinical testing and analysis instruments. The company develops, produces, and sells a range of diagnostic equipment, including urine and stool analyzers, body fluid analyzers, and reproductive tract secretion analyzers, alongside related reagents and consumables. With 545 employees, it serves domestic and international markets, focusing on medical and health institutions for diagnostic solutions. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's AVE Science & Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co